Company news

Acumen Pharmaceuticals, Inc. news in 2026

Acumen Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Acumen Pharmaceuticals Announces Topline Results from Phase 2 ALTITUDE-AD Clinical Trial of Sabirnetug (ACU193) for the Treatment of Early Alzheimer’s Disease; Trial Did Not Meet Primary Endpoint

October 30, 2026

Acumen Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

October 26, 2026

Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

October 22, 2026

Acumen Pharmaceuticals to Report Third Quarter Financial Results on October 26, 2026

October 19, 2026

Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026

September 10, 2026

Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights

August 12, 2026

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026

August 5, 2026

Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

July 15, 2026

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

July 7, 2026

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease

June 16, 2026

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

May 12, 2026

Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

May 7, 2026

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

May 5, 2026

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

March 26, 2026

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

March 19, 2026

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 17, 2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

March 15, 2026

Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

March 10, 2026

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

March 3, 2026

Calls in 2026

Decks in 2026